ProCE Banner Activity

How I Manage Interstitial Lung Disease Associated With Trastuzumab Deruxtecan in My Patients With HER2-Positive MBC

Clinical Thought
How confident are you in managing patients who experience interstitial lung disease while receiving trastuzumab deruxtecan?

Released: September 10, 2020

Expiration: September 09, 2021

Share

Faculty

Adam M. Brufsky

Adam M. Brufsky, MD, PhD

Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Adam M. Brufsky, MD, PhD

Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

Adam M. Brufsky, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Puma, Roche, and Seattle Genetics.